Medical therapy of acromegaly: Efficacy and safety of somatostatin analogues

Drugs

Volumn 69, Issue 16, 2009, Pages 2207-2226

  Feelders, Richard A ^a   Hofland, Leo J ^a   Van Aken, Maarten O ^a   Neggers, Sebastian J ^a   Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Van Der Lely, Aart Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 230A760; BIM 23A387; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; BILIARY TRACT DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; FLATULENCE; GALLSTONE; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; MUSCLE CRAMP; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE LESION; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; MALE; OCTREOTIDE; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 70350504344     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318510-000000000-00000     Document Type: Review

References (130)

1. Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355: 2558-2573
2. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 3013-3018
3. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12: 71-79
4. Gola M, Doga M, Bonadonna S, et al. Neuroendocrine tu-mors secreting growth hormone-releasing hormone: patho-physiological and clinical aspects. Pituitary 2006; 9 (3): 221-229
5. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003; 13: 171-184
6. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endo-crinol Metab 2000; 85: 526-529
7. Freda PU, Landman RE, Sundeen RE, et al. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 2001; 4: 163-171
8. Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acro-megaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87: 3537-3542
9. Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1000 operations. Neuroendocrinology 2006; 83: 230-239
10. Freda PU. How effective are current therapies for acro-megaly? Growth Horm IGF Res 2003; 13Suppl.A:S144-51
11. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171-1177
12. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-1759
13. Brazeau P, Vale W, Burgus R, et al. Hypothalamic poly-peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79
14. Sevarino KA, Felix R, Banks CM, et al. Cell-specific pro-cessing of preprosomatostatin in cultured neuroendocrine cells. J Biol Chem 1987; 262: 4987-4993
15. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198
16. Kumar U, Laird D, Srikant CB, et al. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer im-munofluorescence confocal microscopy. Endocrinology 1997; 138: 4473-4476
17. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995; 56: 333-342
18. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-1392
19. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomato-troph lineage. J Clin Endocrinol Metab 1994; 79: 724-729
20. Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures: differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-798
21. Broglio F, Arvat E, Benso A, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J Clin Endocrinol Metab 2002; 87: 3783-3790
22. Benso A, Gottero C, Prodam F, et al. Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans. J Endocrinol Invest 2003; 26: 599-603
23. Gottero C, Prodam F, Destefanis S, et al. Cortistatin-17 and-14 exert the same endocrine activities as somatostatin in humans. Growth Horm IGF Res 2004; 14: 382-387
24. Ben-Shlomo A, Zhou C, Pichurin O, et al. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol 2009; 23: 337-348
25. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59: 1148-1151
26. Moyse E, Le Dafniet M, Epelbaum J, et al. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 1985; 61: 98-103
27. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somato-statin receptor status. J Clin Endocrinol Metab 1989; 68: 844-850
28. Thodou E, Kontogeorgos G, Theodossiou D, et al. Map-ping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 2006; 59: 274-279
29. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781-792
30. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone-and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89: 1577-1585
31. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007; 156: 65-74
32. Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-2392
33. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somato-statin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86: 140-145
34. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new soma-tostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004; 89: 638-645
35. Ren SG, Taylor J, Dong J, et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88: 4239-4245
36. Zatelli MC, Piccin D, Tagliati F, et al. Somatostatin re-ceptor subtype 1 selective activation in human growth hormone (GH)-and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003; 88: 2797-2802
37. Matrone C, Pivonello R, Colao A, et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrino-logy 2004; 79: 142-148
38. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005; 153: 135-141
39. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between anti-proliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007; 92: 1592-1599
40. Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006; 13: 955-962
41. Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006; 155: 371-379
42. Florio T, Thellung S, Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003; 59: 115-128
43. Danesi R, Agen C, Benelli U, et al. Inhibition of experimen-tal angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997; 3: 265-272
44. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57: 425-441
45. Grass P, Marbach P, Bruns C, et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45: 27-30
46. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-699
47. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003; 63: 2473-2499
48. Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005; 45: 836-844
49. Tomlinson B, Thomas NG, Lan IW, et al. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Clin Pharmaco-kinet 2006; 45: 1003-1011
50. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 1990; 19: 319-332
51. Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79: 145-151
52. Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80: 3267-3272
53. Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide auto-gel). Exp Clin Endocrinol Diabetes 2005; 113: 139-144
54. Caron P, Cogne M, Raingeard I, et al. Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006; 64: 209-214
55. Lucas T, Astorga R. Efficacy of lanreotide autogel ad-ministered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006; 65: 320-326
56. Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 4465-4473
57. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957-2968
58. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002; 87: 99-104 (Pubitemid 34084677)
59. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004; 150: 473-480
60. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004; 151: 317-324
61. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007; 67: 512-519
62. van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004; 150: 489-495
63. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008; 68: 473-480
64. Biermasz NR, van den Oever NC, Frolich M, et al. Sando-statin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 2003; 58: 288-295
65. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2004; 61: 224-231
66. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87: 4554-4563
67. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91: 1397-1403
68. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006; 64: 342-351
69. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007; 67: 282-289
70. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acro-megaly. Clin Endocrinol (Oxf) 2007; 66: 859-868
71. Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acro-megaly. J Clin Endocrinol Metab 2006; 91: 85-92
72. Ayuk J, Stewart SE, Stewart PM, et al. Efficacy of sando-statin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004; 60: 375-381
73. Jallad RS, Musolino NR, Kodaira S, et al. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 2007; 67: 310-315
74. Karavitaki N, Turner HE, Adams CB, et al. Surgical de-bulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008; 68: 970-975
75. Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 2005; 62: 282-288
76. de Herder WW, Taal HR, Uitterlinden P, et al. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 2005; 153: 67-71
77. Fougner SL, Borota OC, Berg JP, et al. The clinical res-ponse to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008; 68: 458-465
78. Koper JW, Hofland LJ, van Koetsveld PM, et al. De-sensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Res 1990; 50: 6238-6242
79. Zatelli MC, Piccin D, Ambrosio MR, et al. Anti-proliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 2006; 9: 27-34
80. Thapar K, Kovacs KT, Stefaneanu L, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multi-center randomized trial. Mayo Clin Proc 1997; 72: 893-900
81. Losa M, Ciccarelli E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86: 5194-5200
82. Cap J, Cerman J, Nemecek S, et al. The influence of treat-ment with somatostatin analogues on morphology, pro-liferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 2003; 10: 444-448
83. Bevan JS. Clinical review: the antitumoral effects of so-matostatin analog therapy in acromegaly. J Clin Endo-crinol Metab 2005; 90: 1856-1863
84. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90: 4405-4410
85. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992; 117: 711-718
86. Cozzi R, Attanasio R, Montini M, et al. Four-year treat-ment with octreotide-long-acting repeatable in 110 acro-megalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003; 88: 3090-3098
87. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 2003; 58: 471-481
88. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91: 2112-2118
89. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001; 145: 137-145
90. Verhelst JA, Pedroncelli AM, Abs R, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000; 143: 577-584
91. Baldelli R, Battista C, Leonetti F, et al. Glucose homeo-stasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003; 59: 492-499
92. Steffin B, Gutt B, Bidlingmaier M, et al. Effects of the long-acting somatostatin analogue lanreotide autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 2006; 155: 73-78
93. Fassnacht M, Capeller B, Arlt W, et al. LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf) 2001; 55: 411-415
94. Schmid HA. Pasireotide (SOM230): development, mechan-ism of action and potential applications. Mol Cell Endo-crinol 2008; 286: 69-74
95. Weckbecker G, Briner U, Lewis I, et al. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002; 143: 4123-4130
96. Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994; 79: 461-465
97. Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157
98. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somato-troph adenoma cells. J Clin Endocrinol Metab 2002; 87: 5545-5552
99. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005; 28: 21-7
100. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000; 53: 577-86
101. Ambrosio MR, Franceschetti P, Bondanelli M, et al. Effi-cacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism 2002; 51: 387-93
102. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86: 2779-86
103. Bonadonna S, Doga M, Gola M, et al. Diagnosis and treatment of acromegaly and its complications: consensus guidelines. J Endocrinol Invest 2005; 28: 43-7
104. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153: 737-40
105. Clemmons DR, Chihara K, Freda PU, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003; 88: 4759-67
106. Giustina A, Melmed S. Acromegaly consensus: the next steps. J Clin Endocrinol Metab 2003; 88: 1913-4
107. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003; 26: 1242-7
108. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002; 87: 4054-8
109. Abosch A, Tyrrell JB, Lamborn KR, et al. Transsphenoi-dal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83: 3411-8
110. Swearingen B, Barker 2nd FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and ad-junctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-26
111. Abbassioun K, Amirjamshidi M, Mehrazin A, et al. A prospective analysis of 151 cases of patients with acro-megaly operated by one neurosurgeon: a follow-up of more than 23 years. Surg Neurol 2006; 66: 26-31
112. Freda PU, Wardlaw SL, Post KD. Long-term endo-crinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89: 353-8
113. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatosta-tin analogs. Eur J Endocrinol 2005; 152: 61-6
114. Petersenn S, Buchfelder M, Reincke M, et al. Results of surgical and somatostatin analog therapy and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol 2008; 159 (5): 525-32
115. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-40
116. Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neuro-surg 2006; 104: 899-906 11
117. Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 2005; 147: 485-93
118. Kleinberg DL. Primary therapy for acromegaly with so-matostatin analogs and a discussion of novel peptide analogs. Rev Endocr Metab Disord 2005; 6: 29-37
119. Stevenaert A, Beckers A. Presurgical octreotide treat-ment in acromegaly. Acta Endocrinol (Copenh) 1993; 129 Suppl. 1: 18-20
120. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Pre-operative octreotide treatment in newly diagnosed acro-megalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008; 93: 2984-90
121. Burton CM, Nemergut EC. Anesthetic and critical care management of patients undergoing pituitary surgery. Front Horm Res 2006; 34: 236-55
122. Kreutzer J, Vance ML, Lopes MB, et al. Surgical man-agement of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86: 4072-7
123. Nemergut EC, Dumont AS, Barry UT, et al. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesth Analg 2005; 101: 1170-81
124. Herman-Bonert VS, Zib K, Scarlett JA, et al. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000; 85: 2958-61
125. van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001; 86: 478-81
126. Leung KC, Doyle N, Ballesteros M, et al. Insulin regula-tion of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000; 85: 4712-20
127. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endo-crinol Metab 2005; 90: 5627-31
128. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvi-somant in active acromegaly. Lancet 2005; 365: 1644-6
129. Drake WM, Berney DM, Kovacs K, et al. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. EurJEndocrinol 2005; 153: 203-5
130. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008; 93: 3853-9